Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Ana Blanca, Antonio Lopez-Beltran

Research output: Contribution to journalReview article

Abstract

Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.

Original languageEnglish (US)
Pages (from-to)1507-1521
Number of pages15
JournalImmunotherapy
Volume11
Issue number17
DOIs
StatePublished - Jan 1 2019

    Fingerprint

Keywords

  • atezolizumab
  • avelumab
  • combination strategies
  • immune-checkpoint inhibitors
  • immunotherapy
  • ipilimumab
  • metastatic renal cell
  • nivolumab
  • pembrolizumab
  • renal cell carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Massari, F., Nunno, V. D., Mollica, V., Montironi, R., Cheng, L., Cimadamore, A., Blanca, A., & Lopez-Beltran, A. (2019). Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 11(17), 1507-1521. https://doi.org/10.2217/imt-2019-0115